Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Filings indexed 286 across all filing types
Latest filing 2025-10-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January-September 2025' and contains detailed financial statements, including net sales, EBITDA, operating income, and cash flow analysis for the third quarter and the nine-month period. It also includes management commentary, business updates, and clinical trial status. This meets the criteria for an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. 9M 2025
2025-10-23 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) from the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding by Swedbank Robur Fonder AB in Xvivo Perfusion Aktiebolag, specifically noting a sale that caused the holding to drop below a 5% threshold. This is a classic major shareholding notification.
2025-08-08 Swedish
Fördröjning i CE-godkännandeprocessen för XVIVOs perfusionslösning för hjärtpreservation
Legal Proceedings Report Classification · 99% confidence The document is a press release issued by XVIVO Perfusion AB regarding a delay in the CE-approval process for their heart preservation solution due to regulatory consultation requirements. It provides details on the regulatory status, the impact of the delay, and quotes from the CEO. While it discusses regulatory matters, it is a specific corporate announcement regarding a business development/regulatory hurdle rather than a formal legal proceeding report or a general regulatory filing. Given the nature of the announcement regarding a specific operational/regulatory update, it fits best under 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'Legal Proceedings' if interpreted strictly, but RNS is the standard fallback for such corporate news releases in this taxonomy.
2025-07-28 Swedish
Delay in CE approval for XVIVO’s perfusion solution for heart preservation
Legal Proceedings Report Classification · 99% confidence The document is a regulatory announcement regarding a delay in CE approval for a medical device. It explicitly states it is being made public pursuant to the EU Market Abuse Regulation and includes a timestamp for publication. While it discusses regulatory matters, it is a specific corporate announcement rather than a legal proceeding report or a general filing. Given the nature of the announcement regarding regulatory status and the requirement for public disclosure, it fits best as a Regulatory Filing (RNS).
2025-07-28 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport januari – juni 2025' (Interim Report January – June 2025) for XVIVO Perfusion AB. It contains comprehensive financial statements, including income statements, balance sheet data, cash flow analysis, and management commentary on business performance for the second quarter and the first half of the year. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-07-11 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January–June 2025' and contains comprehensive financial data, including net sales, gross margins, EBIT, EBITDA, net profit, and cash flow for the second quarter and the first half of 2025. It also includes management commentary, business updates, and clinical trial status. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial statements and analysis for a period shorter than a full fiscal year. H1 2025
2025-07-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.